Presentation and Disease Course of Childhood-Onset Versus Adult-Onset Takayasu Arteritis.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 10 2017
accepted: 07 08 2018
pubmed: 14 8 2018
medline: 5 11 2019
entrez: 14 8 2018
Statut: ppublish

Résumé

To compare the clinical features, efficacy and safety of treatment regimens, and outcomes of childhood- and adult-onset Takayasu arteritis (TAK). The study was designed as a retrospective cohort study comparing patients with childhood-onset TAK (from 1986 onward) to patients with adult-onset TAK (from 1988 onward) who were followed up until 2014 or 2015 at 4 centers in Ontario, Canada. Demographic, clinical, laboratory, and angiographic features, treatment regimens, and outcomes were recorded throughout the course of the disease. Disease activity and damage scores were completed retrospectively. Twenty-nine children and 48 adults (median age at diagnosis 12.1 years and 31.2 years, respectively) were included. A lower predominance of females was observed among the childhood-onset TAK cohort (76% versus 100% of patients with adult-onset TAK; P < 0.01), and children had a shorter delay to diagnosis (median 6.0 months versus 12.2 months for adults; P = 0.03). The distribution of vascular involvement was also different, with children having significantly more aortic and renal artery involvement and a higher frequency of arterial hypertension. Relapses in the first year after diagnosis were common both in children (39%) and in adults (28%). Two children, but no adults, died. Childhood-onset TAK has a lower female predominance and a higher frequency of aortic and renal involvement compared to adult-onset TAK. Relapses and disease burden were high in both groups, corroborating the need for careful monitoring of disease activity and aggressive therapeutic management.

Identifiants

pubmed: 30101446
doi: 10.1002/art.40690
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

315-323

Subventions

Organisme : Swiss League against Rheumatism
Pays : International
Organisme : Rhyner-Bangerter Foundation
Pays : International
Organisme : Foundation W!
Pays : International
Organisme : Alberta Children's Hospital Research Institute Foundation
Pays : International
Organisme : Dawson Jarock Foundation
Pays : International
Organisme : Hak-Ming and Deborah Chiu Chair in Pediatric Translational Research
Pays : International
Organisme : Starr Foundation
Pays : International
Organisme : SickKids Foundation
Pays : International

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2018, American College of Rheumatology.

Auteurs

Florence A Aeschlimann (FA)

The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Lillian Barra (L)

St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada.

Roaa Alsolaimani (R)

St. Joseph's Health Care London and University of Western Ontario, London, Ontario, Canada.

Susanne M Benseler (SM)

Alberta Children's Hospital and University of Calgary, Calgary, Alberta, Canada.

Diane Hebert (D)

The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Nader Khalidi (N)

St. Joseph's Healthcare and McMaster University, Hamilton, Ontario, Canada.

Ronald M Laxer (RM)

The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Damien Noone (D)

The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Christian Pagnoux (C)

Mount Sinai Hospital and University of Toronto, Toronto, Ontario, Canada.

Marinka Twilt (M)

Alberta Children's Hospital and University of Calgary, Calgary, Alberta, Canada.

Rae S M Yeung (RSM)

The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH